Vantia Therapeutics

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

Wet age-related macular degeneration (AMD) is receiving a lot of attention from industry, scientists and Wall Street these days, thanks to the enormous and rapid commercial success of new treatments f

The legacy of Eyetech Inc. continues, as its successor, Ophthotech Corp. , has raised $175 million to fund a huge Phase III trial for its wet age-related macular degeneration (AMD) candidate,

Financings In the third quarter of 2011, biopharma start-ups raised $299 million – $48 million more than last quarter, with more than half of the funding going to Series A rounds. ( See Exhibit 1. )Me